1/3

Cipla
Cipla Ltd.
Mumbai Central
Mumbai 400 008

10th May, 2012

(1) Bombay Stock Exchange Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

Dear Sirs,

Please find enclosed copy of Press Release dated 10th May, 2012.

Kindly acknowledge the receipt.

Thank you,

Yours faithfully,
For Cipla Limited

M. A. Sanghvi


Mital Sanghvi
Company Secretary


Encl: as above


Phone : (9122) 23082891, 23095521 • Fax : (9122) 23070013, 23070393, 23070385


(Q4 FY1011)

- Profit after tax grew by 36.3% to Rs. 292 cr during Q4 FY1112, up from Rs. 214 cr (Q4 FY1011)









Profit & Loss Highlights:

- Material cost at 42.0% of Total Sales decreased by 7.2% during Q4 FY1112 as compared to Q4 FY1011.
- Operating margins increased by 37.4% and is at 21.1% of Income from Operations during Q4 FY1112 as compared to 17.2% during Q4 FY1011.
- Profit after tax increased by 36.3% to Rs. 292 cr during Q4 FY1112 as compared to Rs. 214 cr during Q4 FY1011.

Performance Review:

Domestic business:

- Domestic revenues grew by 15.5% to Rs. 754 cr during Q4 FY1112, up from Rs. 652 cr during Q4 FY1011.
- The growth in domestic revenues were largely on account of growth in anti-asthma, anti-biotics, expectorants and anti-inflammatory therapy segments.

International business:

- Exports of formulations grew by 15.1% to Rs. 855 cr during Q4 FY1112, up from Rs. 743 cr during Q4 FY1011.
- Exports of APIs degrew by 1.0% to Rs. 230 cr during Q4 FY1112, from Rs. 232 cr during Q4 FY1011.
- The growth in export revenues were primarily due to growth in anti-asthma & anti-malarial segments.